Answers are grounded in this paper and cite their sources.
Background & Aims Chemoimmunotherapy has emerged as the first-line therapy for unresectable intrahepatic cholangiocarcinoma (ICC). However, durable clinical responses are observed in fewer than 30% of patients, necessitating biomarkers of survival benefit. The aim of this study was to develop and validate a pathomics-based prognostic signature for ICC patients receiving chemoimmunotherapy. Methods This multicenter study included ICC patients with biopsy samples. Pathomics features were extracted from digital H&E-stained images, and the pathomics signature for ICC (PS-ICC) was developed by machine learning. SHapley Additive exPlanations provided algorithmic explanation, and The Cancer Genome Atlas database supported biological interpretation. Compared with radiologic response, we explore PS-ICC's potential as surrogate index. Results With pre-treatment specimens, 189 patients receiving chemoimmunotherapy were included. Univariate Cox analysis demonstrated that the PS-ICC status from a pathomics-driven machine learning model was associated with overall survival (OS) in patients with unresectable ICC undergoing chemoimmunotherapy (training cohort: hazard ratios (HR)=0.09, 95% Confidence interval (95%CI) 0.05-0.14, P<0.001; validation cohort: HR=0.20, 95%CI 0.08-0.47, P<0.001). PS-ICC characterized tumor microenvironment heterogeneity, with lower scores correlating to reduced M0 macrophage infiltration (P=0.043) and programmed death-ligand 1 expression and programmed death-1 checkpoint pathways (P=0.002). Additionally, PS-ICC status could serve as a surrogate marker for OS compared to the Response Evaluation Criteria in Solid Tumors Version1.1 at 3-month post-treatment (training cohort: area under the curve at 1-year: 0.868 vs. 0.701; 2-year: 0.787 vs. 0.694). The PS-ICC-integrated nomogram outperformed conventional prognostic model in accuracy (Concordance index: 0.80 vs. 0.71). Conclusions The PS-ICC demonstrates potential as a surrogate endpoint for survival prediction in patients with ICC undergoing chemoimmunotherapy, with biological plausibility evidenced by its tumor microenvironment associations. Prospective trials are warranted to confirm clinical utility. Impact and implications This study developed and validated a machine learning-based pathomics signature that accurately predicts overall survival in ICC patients receiving chemoimmunotherapy. The pathomics signature for ICC provides a biologically grounded, pretreatment biomarker to stratify patients for chemoimmunotherapy, potentially reducing overtreatment and guiding personalized strategies. By demonstrating strong correlation with overall survival, this signature could serve as a potential surrogate endpoint in clinical trials, thereby accelerating drug development. While its link to immune pathways may inform novel therapeutic targets in ICC. Prospective validation is needed for clinical adoption.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: